Tawit Suriyo

Dr. Tawit Suriyo

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
STSiriporn Thongprakaisang
Siriporn Thongprakaisang
ATApinya Thiantanawat
Apinya Thiantanawat
NRNuchanart Rangkadilok
Nuchanart Rangkadilok
TSTawit Suriyo
Tawit Suriyo
JSJutamaad Satayavivad
Jutamaad Satayavivad

3 August 2015 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
PSPacharapan Sonthithai
Pacharapan Sonthithai
TSTawit Suriyo
Tawit Suriyo
ATApinya Thiantanawat
Apinya Thiantanawat
PWPiyajit Watcharasit
Piyajit Watcharasit
MRMathuros Ruchirawat
Mathuros Ruchirawat
JSJutamaad Satayavivad
Jutamaad Satayavivad

1 February 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NKNongluk Kunworarath
Nongluk Kunworarath
NRNuchanart Rangkadilok
Nuchanart Rangkadilok
TSTawit Suriyo
Tawit Suriyo
ATApinya Thiantanawat
Apinya Thiantanawat
JSJutamaad Satayavivad
Jutamaad Satayavivad

1 August 2018 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
NSNarongrit Sritana
Narongrit Sritana
TSTawit Suriyo
Tawit Suriyo
JKJantamas Kanitwithayanun
Jantamas Kanitwithayanun
BSBenjaporn Homkajorn Songvasin
Benjaporn Homkajorn Songvasin
ATApinya Thiantanawat
Apinya Thiantanawat
JSJutamaad Satayavivad
Jutamaad Satayavivad

1 December 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NPNanthanit Pholphana
Nanthanit Pholphana
DPDuangchit Panomvana
Duangchit Panomvana
NRNuchanart Rangkadilok
Nuchanart Rangkadilok
TSTawit Suriyo
Tawit Suriyo
PPPorranee Puranajoti
Porranee Puranajoti
JSJutamaad Satayavivad
Jutamaad Satayavivad

27 March 2015 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
SASumet Amonyingcharoen
Sumet Amonyingcharoen
TSTawit Suriyo
Tawit Suriyo
ATApinya Thiantanawat
Apinya Thiantanawat
PWPiyajit Watcharasit
Piyajit Watcharasit
JSJutamaad Satayavivad
Jutamaad Satayavivad
Cholangiocarcinoma (CCA) is a malignant cancer of the biliary tract and its occurrence is associated with chronic cholestasis which causes an elevation of bile acids in the liver and bile duct. The present study aimed to investigate the role and mechanistic effect of bile acids on the CCA cell growth. Intrahepatic CCA cell lines, RMCCA-1 and HuCCA-1, were treated with bile acids and their metabolites to determine the growth promoting effect. Cell viability, cell cycle analysis, EdU incorporation assays were conducted. Intracellular signaling proteins were detected by western immunoblotting. Among eleven forms of bile acids and their metabolites, only taurolithocholic acid (TLCA) concentration dependently (1-40 µM) increased the cell viability of RMCCA-1, but not HuCCA-1 cells. The cell cycle analysis showed induction of cells in the S phase and the EdU incorporation assay revealed induction of DNA synthesis in the TLCA-treated RMCCA-1 cells. Moreover, TLCA increased the phosphorylation of EGFR, ERK 1/2 and also increased the expression of cyclin D1 in RMCCA-1 cells. Furthermore, TLCA-induced RMCCA-1 cell growth could be inhibited by atropine, a non-selective muscarinic acetylcholine receptor (mAChR) antagonist, AG 1478, a specific EGFR inhibitor, or U 0126, a specific MEK 1/2 inhibitor. These results suggest that TLCA induces CCA cell growth via mAChR and EGFR/EKR1/2 signaling pathway. Moreover, the functional presence of cholinergic system plays a certain role in TLCA-induced CCA cell growth.